Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford , Oxford, UK.
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford, UK.
Clin Exp Optom. 2021 Jan;104(1):90-94. doi: 10.1111/cxo.13087.
Choroideremia is a progressive X-linked inherited rod-cone dystrophy. Patients present with nyctalopia and progressive visual field loss, but visual acuity remains well preserved early on. This study showed that low-luminance visual acuity may be a useful clinical outcome measure during earlier disease stages.
Choroideremia is a progressive X-linked inherited rod-cone dystrophy. Patients present with nyctalopia and progressive visual field loss. However, visual acuity remains well preserved until late in the disease process, limiting its usefulness as a clinical trial endpoint across the disease spectrum. Visual acuity measurements under low-luminance and low-contrast conditions may be affected sooner and have been suggested as early markers in other ocular diseases. This study assesses whether low-luminance visual acuity and low-contrast visual acuity provide useful endpoints in choroideremia clinical trials.
Standard high-contrast and low-luminance visual acuity was obtained on 29 choroideremia subjects and 16 healthy controls, using a logMAR chart, set at four metres. Low-luminance visual acuity was tested using a 2.0-log unit neutral density filter, with the same chart set-up, without formal dark adaptation. This was followed by low-contrast visual acuity measured using 1.25 per cent and 2.5 per cent low-contrast logMAR charts placed also at four metres. Data from the right eyes only were analysed using non-parametric statistics. High-contrast visual acuity minus low-luminance and low-contrast visual acuity provided the low-luminance and low-contrast difference scores.
A higher number of choroideremia subjects were able to complete the low-luminance test than the low-contrast visual acuity tests. Choroideremia subjects had significantly higher low luminance, 2.5 per cent low-contrast and 1.25 per cent low-contrast difference scores compared with controls (p < 0.01, Mann-Whitney U-test); 1.25 per cent low-contrast visual acuity revealed the poorest performance. A strong positive correlation was found between low-luminance and high-contrast visual acuities (ρ = 0.818, p < 0.001) and 2.5 per cent low-contrast and high-contrast visual acuities (ρ = 0.671, p < 0.001).
The low-luminance visual acuity test may be a useful additional clinical trial outcome measure for early-to-moderate disease, when high-contrast visual acuity is preserved.
脉络膜视网膜变性是一种进行性的 X 连锁遗传性视网膜营养不良。患者表现为夜盲和进行性视野丧失,但视力在早期仍保持良好。本研究表明,低亮度视力可能是疾病早期阶段有用的临床结果衡量标准。
脉络膜视网膜变性是一种进行性的 X 连锁遗传性视网膜营养不良。患者表现为夜盲和进行性视野丧失。然而,视力在疾病过程的晚期仍保持良好,限制了其作为整个疾病谱临床试验终点的有用性。在低亮度和低对比度条件下的视力测量可能会更早受到影响,并已被建议作为其他眼部疾病的早期标志物。本研究评估了低亮度视力和低对比度视力是否为脉络膜视网膜变性临床试验的有用终点。
使用 logMAR 图表,在 29 名脉络膜视网膜变性患者和 16 名健康对照者的 4 米处获得标准高对比度和低亮度视力。使用 2.0 对数单位中性密度滤光片在相同的图表设置下进行低亮度视力测试,无需正式暗适应。随后在 4 米处使用 1.25%和 2.5%低对比度 logMAR 图表测量低对比度视力。仅对右眼数据进行非参数统计分析。高对比度视力减去低亮度和低对比度视力提供了低亮度和低对比度差值评分。
与低对比度视力测试相比,更多的脉络膜视网膜变性患者能够完成低亮度测试。与对照组相比,脉络膜视网膜变性患者的低亮度、2.5%低对比度和 1.25%低对比度差值评分显著更高(p<0.01,Mann-Whitney U 检验);1.25%低对比度视力表现最差。低亮度和高对比度视力之间存在很强的正相关性(ρ=0.818,p<0.001),2.5%低对比度和高对比度视力之间也存在很强的正相关性(ρ=0.671,p<0.001)。
当高对比度视力保持良好时,低亮度视力测试可能是早期至中期疾病的有用的额外临床试验结果衡量标准。